apc cy7 rat anti-mouse cd11b mab (m1 Search Results


human mouse cd11b pe cy7  (Multi Sciences (Lianke) Biotech Co Ltd)
94
Multi Sciences (Lianke) Biotech Co Ltd human mouse cd11b pe cy7
Human Mouse Cd11b Pe Cy7, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/Anti-Human%2FMouse+CD11b/10__1016_slash_j__cej__2024__155511-159-11-34
Average 94 stars, based on 1 article reviews
human mouse cd11b pe cy7 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
mlns  (Miltenyi Biotec)
95
Miltenyi Biotec mlns
Mlns, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/CD11b+Antibody%2C+anti-human%2Fmouse/pmc10769841__pnas__2308706120__sapp-56-47-50
Average 95 stars, based on 1 article reviews
mlns - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
anti cd11b apc cy7  (Becton Dickinson)
90
Becton Dickinson anti cd11b apc cy7
<t>CD11b</t> + myeloid populations are expanded in the bone marrow (BM) of multiple myeloma (MM) tumour‐bearing mice, with an increase in Mpo mRNA expression. (A) The proportion of CD11b + myeloid cells within the BM of naïve and i.v. 5TGM1 tumour‐bearing KaLwRij mice, at early (Week 2) and late (Week 4) stage tumour development, were determined by flow cytometry, represented as a % of non‐tumour (GFP neg ) BM cells. (B) Mpo mRNA expression in magnetically activated cell sorting (MACS)‐enriched CD11b + cells isolated from BM of naïve or tumour‐bearing (weeks 2 and 4) mice, normalised to Gapdh . (C) Mpo mRNA expression in CD11b + cells isolated from tumour I mice cultured in the presence or absence of 50% 5TGM1 CM for 72 h. (D) Representative bioluminescent images ( n = 3) from an i.t. tumour model indicating (i) myeloperoxidase (MPO) activity (luminol) colocalised at (ii) sites of MM tumour development (D‐luciferin). Results are shown as the mean ± SEM, n = 3–8 mice/group. One‐way analysis of variance (ANOVA) with Tukey's multiple comparisons test (A, B) or unpaired t ‐test (C) was used to calculate significance, ** p < 0.01, *** p < 0.001, **** p < 0.0001 and ns (non‐significant; p > 0.05). i.v., intravenous, i.t., intratibial.
Anti Cd11b Apc Cy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/anti+cd3/pmc10952523-36-25-27
Average 90 stars, based on 1 article reviews
anti cd11b apc cy7 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
allophycocyanin-cy7-conjugated mouse monoclonal (igg1) anti-human cd11b  (Becton Dickinson)
90
Becton Dickinson allophycocyanin-cy7-conjugated mouse monoclonal (igg1) anti-human cd11b
<t>CD11b</t> + myeloid populations are expanded in the bone marrow (BM) of multiple myeloma (MM) tumour‐bearing mice, with an increase in Mpo mRNA expression. (A) The proportion of CD11b + myeloid cells within the BM of naïve and i.v. 5TGM1 tumour‐bearing KaLwRij mice, at early (Week 2) and late (Week 4) stage tumour development, were determined by flow cytometry, represented as a % of non‐tumour (GFP neg ) BM cells. (B) Mpo mRNA expression in magnetically activated cell sorting (MACS)‐enriched CD11b + cells isolated from BM of naïve or tumour‐bearing (weeks 2 and 4) mice, normalised to Gapdh . (C) Mpo mRNA expression in CD11b + cells isolated from tumour I mice cultured in the presence or absence of 50% 5TGM1 CM for 72 h. (D) Representative bioluminescent images ( n = 3) from an i.t. tumour model indicating (i) myeloperoxidase (MPO) activity (luminol) colocalised at (ii) sites of MM tumour development (D‐luciferin). Results are shown as the mean ± SEM, n = 3–8 mice/group. One‐way analysis of variance (ANOVA) with Tukey's multiple comparisons test (A, B) or unpaired t ‐test (C) was used to calculate significance, ** p < 0.01, *** p < 0.001, **** p < 0.0001 and ns (non‐significant; p > 0.05). i.v., intravenous, i.t., intratibial.
Allophycocyanin Cy7 Conjugated Mouse Monoclonal (Igg1) Anti Human Cd11b, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/hla+dr+pe+antibody/pmc02546821-124-25-31
Average 90 stars, based on 1 article reviews
allophycocyanin-cy7-conjugated mouse monoclonal (igg1) anti-human cd11b - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cd11b apc cy7 antibodies  (Revvity)
97
Revvity cd11b apc cy7 antibodies
<t>CD11b</t> + myeloid populations are expanded in the bone marrow (BM) of multiple myeloma (MM) tumour‐bearing mice, with an increase in Mpo mRNA expression. (A) The proportion of CD11b + myeloid cells within the BM of naïve and i.v. 5TGM1 tumour‐bearing KaLwRij mice, at early (Week 2) and late (Week 4) stage tumour development, were determined by flow cytometry, represented as a % of non‐tumour (GFP neg ) BM cells. (B) Mpo mRNA expression in magnetically activated cell sorting (MACS)‐enriched CD11b + cells isolated from BM of naïve or tumour‐bearing (weeks 2 and 4) mice, normalised to Gapdh . (C) Mpo mRNA expression in CD11b + cells isolated from tumour I mice cultured in the presence or absence of 50% 5TGM1 CM for 72 h. (D) Representative bioluminescent images ( n = 3) from an i.t. tumour model indicating (i) myeloperoxidase (MPO) activity (luminol) colocalised at (ii) sites of MM tumour development (D‐luciferin). Results are shown as the mean ± SEM, n = 3–8 mice/group. One‐way analysis of variance (ANOVA) with Tukey's multiple comparisons test (A, B) or unpaired t ‐test (C) was used to calculate significance, ** p < 0.01, *** p < 0.001, **** p < 0.0001 and ns (non‐significant; p > 0.05). i.v., intravenous, i.t., intratibial.
Cd11b Apc Cy7 Antibodies, supplied by Revvity, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/SureLight+Allophycocyanin-anti-6His+antibody%2C+lyophilized/pm27084569-98-30-33
Average 97 stars, based on 1 article reviews
cd11b apc cy7 antibodies - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
mouse igg 2a,κ anti-mouse nk1.1-fitc  (Becton Dickinson)
90
Becton Dickinson mouse igg 2a,κ anti-mouse nk1.1-fitc
<t>CD11b</t> + myeloid populations are expanded in the bone marrow (BM) of multiple myeloma (MM) tumour‐bearing mice, with an increase in Mpo mRNA expression. (A) The proportion of CD11b + myeloid cells within the BM of naïve and i.v. 5TGM1 tumour‐bearing KaLwRij mice, at early (Week 2) and late (Week 4) stage tumour development, were determined by flow cytometry, represented as a % of non‐tumour (GFP neg ) BM cells. (B) Mpo mRNA expression in magnetically activated cell sorting (MACS)‐enriched CD11b + cells isolated from BM of naïve or tumour‐bearing (weeks 2 and 4) mice, normalised to Gapdh . (C) Mpo mRNA expression in CD11b + cells isolated from tumour I mice cultured in the presence or absence of 50% 5TGM1 CM for 72 h. (D) Representative bioluminescent images ( n = 3) from an i.t. tumour model indicating (i) myeloperoxidase (MPO) activity (luminol) colocalised at (ii) sites of MM tumour development (D‐luciferin). Results are shown as the mean ± SEM, n = 3–8 mice/group. One‐way analysis of variance (ANOVA) with Tukey's multiple comparisons test (A, B) or unpaired t ‐test (C) was used to calculate significance, ** p < 0.01, *** p < 0.001, **** p < 0.0001 and ns (non‐significant; p > 0.05). i.v., intravenous, i.t., intratibial.
Mouse Igg 2a,κ Anti Mouse Nk1.1 Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/isotype+control+antibodies/pmc03212434-410-29-39
Average 90 stars, based on 1 article reviews
mouse igg 2a,κ anti-mouse nk1.1-fitc - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cd11b pe cy7  (Cytek Biosciences)
93
Cytek Biosciences cd11b pe cy7
(A) The initial observation of the proportion of H2-A + cells among immune cells with broad myeloid markers. One experiment; a Student’s t test with Holm-Sidak’s multiple testing correction was used. (B) Representative flow plots illustrate the gating strategy used to identify P1–4 monocyte/macrophage cells. CD45 + , Lin − (CD3, NK1.1, Siglec-F, CD19), <t>CD11b</t> + , CD11c + cells are input. (C–E) Proportion (C and E) and MFI (D) of P1, P2, and P3/4 monocyte/macrophages (C and D) and DCs (D and E) under homeostatic SPF conditions in 9-week-old male and female mice. P3/4 are not shown for PP because they are not CD64 + . n = 6 WT and 5 IEC ΔMHCII . Data are representative of 2 experiments. A Student’s t test with Holm-Sidak’s multiple testing correction was used. (F) As in (C)–(E) but showing the CD11c-negative subset of P3/4 macrophages.
Cd11b Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/PE-Cyanine7+Anti-Human%2FMouse+CD11b/pmc09012449-24-0-5
Average 93 stars, based on 1 article reviews
cd11b pe cy7 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
rat anti-human cd47 b6h12  (Becton Dickinson)
90
Becton Dickinson rat anti-human cd47 b6h12
(A) Marrow macrophages were engineered and mixed with streptavidin beads of 900 nm to 6.7 μm diameter or else with disaggregated tdTom A549 tumors. Beads are opsonized with anti-streptavidin except for a non-targeted control in which SIRPα-inhibited macrophages were incubated with 2.1 μm lacking anti-streptavidin. These were not engulfed. After pre-incubation of the mixtures for up to 150 min, mixtures were plated for 24 hr on top of 5-μm pore transwells. Cells collected from transwell tops and bottoms were stained for <t>CD11b+,F4/80+</t> and analyzed by flow cytometry for engulfment (STAR Methods).
Rat Anti Human Cd47 B6h12, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/anti+cd47/pmc05846676-593-38-44
Average 90 stars, based on 1 article reviews
rat anti-human cd47 b6h12 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
pe-cy7 mouse anti-human cd14  (Becton Dickinson)
90
Becton Dickinson pe-cy7 mouse anti-human cd14
(A) Marrow macrophages were engineered and mixed with streptavidin beads of 900 nm to 6.7 μm diameter or else with disaggregated tdTom A549 tumors. Beads are opsonized with anti-streptavidin except for a non-targeted control in which SIRPα-inhibited macrophages were incubated with 2.1 μm lacking anti-streptavidin. These were not engulfed. After pre-incubation of the mixtures for up to 150 min, mixtures were plated for 24 hr on top of 5-μm pore transwells. Cells collected from transwell tops and bottoms were stained for <t>CD11b+,F4/80+</t> and analyzed by flow cytometry for engulfment (STAR Methods).
Pe Cy7 Mouse Anti Human Cd14, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/anti+cd14/pmc05339735-152-15-25
Average 90 stars, based on 1 article reviews
pe-cy7 mouse anti-human cd14 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
pe cy7 conjugated antibody against mouse cd11b  (Biogems International)
91
Biogems International pe cy7 conjugated antibody against mouse cd11b
Fig. 1. TREM-1 expression was up-regulated in mice infected with Schistosoma japonicum at 6 weeks after infection and then decreased. The number of TREM- 1 + cells in total F4/80 <t>+CD11b+</t> peritoneal macrophages was increased in mice infected with Schistosoma japonicum at 6 weeks, compared to that from uninfected mice (*P < 0.05). Then the number of TREM-1 + cells in total F4/80 +CD11b+ peritoneal macrophages was decreased after 6 weeks after infection.
Pe Cy7 Conjugated Antibody Against Mouse Cd11b, supplied by Biogems International, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/Anti-Human%2FMouse+CD11b+PE-Cyanine7/pm35306429-54-15-24
Average 91 stars, based on 1 article reviews
pe cy7 conjugated antibody against mouse cd11b - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
cd11b pe cy7  (Elabscience Biotechnology)
94
Elabscience Biotechnology cd11b pe cy7
Fig. 1. TREM-1 expression was up-regulated in mice infected with Schistosoma japonicum at 6 weeks after infection and then decreased. The number of TREM- 1 + cells in total F4/80 <t>+CD11b+</t> peritoneal macrophages was increased in mice infected with Schistosoma japonicum at 6 weeks, compared to that from uninfected mice (*P < 0.05). Then the number of TREM-1 + cells in total F4/80 +CD11b+ peritoneal macrophages was decreased after 6 weeks after infection.
Cd11b Pe Cy7, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/PE%2FCyanine7+Anti-Mouse%2FHuman+CD11b+Antibody/pmc13032752-132-10-11
Average 94 stars, based on 1 article reviews
cd11b pe cy7 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
pe cy7 anti mouse cd11b  (4A Biotech)
86
4A Biotech pe cy7 anti mouse cd11b
Fig. 1. TREM-1 expression was up-regulated in mice infected with Schistosoma japonicum at 6 weeks after infection and then decreased. The number of TREM- 1 + cells in total F4/80 <t>+CD11b+</t> peritoneal macrophages was increased in mice infected with Schistosoma japonicum at 6 weeks, compared to that from uninfected mice (*P < 0.05). Then the number of TREM-1 + cells in total F4/80 +CD11b+ peritoneal macrophages was decreased after 6 weeks after infection.
Pe Cy7 Anti Mouse Cd11b, supplied by 4A Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+cy7+rat+anti-mouse+cd11b+mab+(m1/anti+apc+cd19+cy7+mouse/pmc12783320-30-33-49
Average 86 stars, based on 1 article reviews
pe cy7 anti mouse cd11b - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


CD11b + myeloid populations are expanded in the bone marrow (BM) of multiple myeloma (MM) tumour‐bearing mice, with an increase in Mpo mRNA expression. (A) The proportion of CD11b + myeloid cells within the BM of naïve and i.v. 5TGM1 tumour‐bearing KaLwRij mice, at early (Week 2) and late (Week 4) stage tumour development, were determined by flow cytometry, represented as a % of non‐tumour (GFP neg ) BM cells. (B) Mpo mRNA expression in magnetically activated cell sorting (MACS)‐enriched CD11b + cells isolated from BM of naïve or tumour‐bearing (weeks 2 and 4) mice, normalised to Gapdh . (C) Mpo mRNA expression in CD11b + cells isolated from tumour I mice cultured in the presence or absence of 50% 5TGM1 CM for 72 h. (D) Representative bioluminescent images ( n = 3) from an i.t. tumour model indicating (i) myeloperoxidase (MPO) activity (luminol) colocalised at (ii) sites of MM tumour development (D‐luciferin). Results are shown as the mean ± SEM, n = 3–8 mice/group. One‐way analysis of variance (ANOVA) with Tukey's multiple comparisons test (A, B) or unpaired t ‐test (C) was used to calculate significance, ** p < 0.01, *** p < 0.001, **** p < 0.0001 and ns (non‐significant; p > 0.05). i.v., intravenous, i.t., intratibial.

Journal: British Journal of Haematology

Article Title: Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma

doi: 10.1111/bjh.19102

Figure Lengend Snippet: CD11b + myeloid populations are expanded in the bone marrow (BM) of multiple myeloma (MM) tumour‐bearing mice, with an increase in Mpo mRNA expression. (A) The proportion of CD11b + myeloid cells within the BM of naïve and i.v. 5TGM1 tumour‐bearing KaLwRij mice, at early (Week 2) and late (Week 4) stage tumour development, were determined by flow cytometry, represented as a % of non‐tumour (GFP neg ) BM cells. (B) Mpo mRNA expression in magnetically activated cell sorting (MACS)‐enriched CD11b + cells isolated from BM of naïve or tumour‐bearing (weeks 2 and 4) mice, normalised to Gapdh . (C) Mpo mRNA expression in CD11b + cells isolated from tumour I mice cultured in the presence or absence of 50% 5TGM1 CM for 72 h. (D) Representative bioluminescent images ( n = 3) from an i.t. tumour model indicating (i) myeloperoxidase (MPO) activity (luminol) colocalised at (ii) sites of MM tumour development (D‐luciferin). Results are shown as the mean ± SEM, n = 3–8 mice/group. One‐way analysis of variance (ANOVA) with Tukey's multiple comparisons test (A, B) or unpaired t ‐test (C) was used to calculate significance, ** p < 0.01, *** p < 0.001, **** p < 0.0001 and ns (non‐significant; p > 0.05). i.v., intravenous, i.t., intratibial.

Article Snippet: Total BM was collected from naïve or 5TGM1 tumour‐bearing KaLwRij mice at experimental end‐points, and 1 × 10 6 cells were stained with mouse monoclonal anti‐CD11b APC‐Cy7 (BD Biosciences), anti‐Ly‐6C BV421 and anti‐Ly‐6G PE‐Cy7 antibodies (Biolegend) and subjected to analysis by flow cytometry using the LSRFortessa X‐20 flow cytometer (BD Biosciences).

Techniques: Expressing, Flow Cytometry, FACS, Isolation, Cell Culture, Activity Assay

Inflammation provides a pro‐tumorigenic niche within the bone marrow (BM) and promotes multiple myeloma (MM) plasma cell (PC) homing. (A) Representative bioluminescence image indicating myeloperoxidase activity via luminol injection 24 h post‐i.t.‐induced inflammation. (B) The proportion of CD11b + myeloid cells within the BM 24 h following i.t. was determined by flow cytometry. Graph shows comparison of undamaged contralateral tibia to i.t. damaged tibia in the same mouse. (C) 24 h after sham i.t. injection, an independent cohort of mice were injected with 5TGM1 MM PCs i.v. and BM of the sham i.t and contralateral tibiae were analysed after 24 h by flow cytometry to quantify the number of GFP + 5TGM1 MM PCs per 10 6 BM cells. Results are shown as the mean ± SEM, n = 5–8 mice/group. Paired t ‐test was used to calculate significance, ** p < 0.01. i.v., intravenous, i.t., intratibial.

Journal: British Journal of Haematology

Article Title: Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma

doi: 10.1111/bjh.19102

Figure Lengend Snippet: Inflammation provides a pro‐tumorigenic niche within the bone marrow (BM) and promotes multiple myeloma (MM) plasma cell (PC) homing. (A) Representative bioluminescence image indicating myeloperoxidase activity via luminol injection 24 h post‐i.t.‐induced inflammation. (B) The proportion of CD11b + myeloid cells within the BM 24 h following i.t. was determined by flow cytometry. Graph shows comparison of undamaged contralateral tibia to i.t. damaged tibia in the same mouse. (C) 24 h after sham i.t. injection, an independent cohort of mice were injected with 5TGM1 MM PCs i.v. and BM of the sham i.t and contralateral tibiae were analysed after 24 h by flow cytometry to quantify the number of GFP + 5TGM1 MM PCs per 10 6 BM cells. Results are shown as the mean ± SEM, n = 5–8 mice/group. Paired t ‐test was used to calculate significance, ** p < 0.01. i.v., intravenous, i.t., intratibial.

Article Snippet: Total BM was collected from naïve or 5TGM1 tumour‐bearing KaLwRij mice at experimental end‐points, and 1 × 10 6 cells were stained with mouse monoclonal anti‐CD11b APC‐Cy7 (BD Biosciences), anti‐Ly‐6C BV421 and anti‐Ly‐6G PE‐Cy7 antibodies (Biolegend) and subjected to analysis by flow cytometry using the LSRFortessa X‐20 flow cytometer (BD Biosciences).

Techniques: Activity Assay, Injection, Flow Cytometry, Comparison

(A) The initial observation of the proportion of H2-A + cells among immune cells with broad myeloid markers. One experiment; a Student’s t test with Holm-Sidak’s multiple testing correction was used. (B) Representative flow plots illustrate the gating strategy used to identify P1–4 monocyte/macrophage cells. CD45 + , Lin − (CD3, NK1.1, Siglec-F, CD19), CD11b + , CD11c + cells are input. (C–E) Proportion (C and E) and MFI (D) of P1, P2, and P3/4 monocyte/macrophages (C and D) and DCs (D and E) under homeostatic SPF conditions in 9-week-old male and female mice. P3/4 are not shown for PP because they are not CD64 + . n = 6 WT and 5 IEC ΔMHCII . Data are representative of 2 experiments. A Student’s t test with Holm-Sidak’s multiple testing correction was used. (F) As in (C)–(E) but showing the CD11c-negative subset of P3/4 macrophages.

Journal: Cell reports

Article Title: Epithelial-myeloid exchange of MHC class II constrains immunity and microbiota composition

doi: 10.1016/j.celrep.2021.109916

Figure Lengend Snippet: (A) The initial observation of the proportion of H2-A + cells among immune cells with broad myeloid markers. One experiment; a Student’s t test with Holm-Sidak’s multiple testing correction was used. (B) Representative flow plots illustrate the gating strategy used to identify P1–4 monocyte/macrophage cells. CD45 + , Lin − (CD3, NK1.1, Siglec-F, CD19), CD11b + , CD11c + cells are input. (C–E) Proportion (C and E) and MFI (D) of P1, P2, and P3/4 monocyte/macrophages (C and D) and DCs (D and E) under homeostatic SPF conditions in 9-week-old male and female mice. P3/4 are not shown for PP because they are not CD64 + . n = 6 WT and 5 IEC ΔMHCII . Data are representative of 2 experiments. A Student’s t test with Holm-Sidak’s multiple testing correction was used. (F) As in (C)–(E) but showing the CD11c-negative subset of P3/4 macrophages.

Article Snippet: CD11b PE-Cy7, clone M1/70 , Tonbo Biosciences , Cat#60-0112; RRID: AB_2621836.

Techniques:

(A) The proportion of mT + mG + MNP subsets in the siLP. Cells subsets are pregated on Live, Dump − (CD3, CD19, NK1.1, Ly6G), CD45 + , and MHC class II + . Representative flow plots are shown for CD11c + macrophages and DCs. Two-way ANOVA with Holm-Sidak correction was used. (B) Representative image panel of cells from imaging flow cytometry analysis of mT + mG + MNPs. Cells are Live, Dump − (CD3, IgM), CD45 + , and MHC class II + . No CD11c or CD11b subsetting due to reduced channel availability on imaging cytometry platform was used. (C) A cartoon schematic of mixed MHC class II bone-marrow transfer experiments. (D) The percentage of host MHC class II (H2-A b ) positive donor cells (HLA-DR) in the siLP. Cells are CD11c − P3/P4 macrophages gated as in previous figures. A representative plot (pregated on CD45 + , Dump-, CD11b + /CD11c + , and CX3CR1 + /CD64 + cells) is shown, along with an overlay of the H2-A b isotype control demonstrating the MHC class II-haplotype specificity of the staining.

Journal: Cell reports

Article Title: Epithelial-myeloid exchange of MHC class II constrains immunity and microbiota composition

doi: 10.1016/j.celrep.2021.109916

Figure Lengend Snippet: (A) The proportion of mT + mG + MNP subsets in the siLP. Cells subsets are pregated on Live, Dump − (CD3, CD19, NK1.1, Ly6G), CD45 + , and MHC class II + . Representative flow plots are shown for CD11c + macrophages and DCs. Two-way ANOVA with Holm-Sidak correction was used. (B) Representative image panel of cells from imaging flow cytometry analysis of mT + mG + MNPs. Cells are Live, Dump − (CD3, IgM), CD45 + , and MHC class II + . No CD11c or CD11b subsetting due to reduced channel availability on imaging cytometry platform was used. (C) A cartoon schematic of mixed MHC class II bone-marrow transfer experiments. (D) The percentage of host MHC class II (H2-A b ) positive donor cells (HLA-DR) in the siLP. Cells are CD11c − P3/P4 macrophages gated as in previous figures. A representative plot (pregated on CD45 + , Dump-, CD11b + /CD11c + , and CX3CR1 + /CD64 + cells) is shown, along with an overlay of the H2-A b isotype control demonstrating the MHC class II-haplotype specificity of the staining.

Article Snippet: CD11b PE-Cy7, clone M1/70 , Tonbo Biosciences , Cat#60-0112; RRID: AB_2621836.

Techniques: Imaging, Flow Cytometry, Cytometry, Control, Staining

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Epithelial-myeloid exchange of MHC class II constrains immunity and microbiota composition

doi: 10.1016/j.celrep.2021.109916

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: CD11b PE-Cy7, clone M1/70 , Tonbo Biosciences , Cat#60-0112; RRID: AB_2621836.

Techniques: Virus, Recombinant, SYBR Green Assay, Cell Isolation, DNA Extraction, Enzyme-linked Immunosorbent Assay, Sequencing, Expressing, Software, Luminex

(A) Marrow macrophages were engineered and mixed with streptavidin beads of 900 nm to 6.7 μm diameter or else with disaggregated tdTom A549 tumors. Beads are opsonized with anti-streptavidin except for a non-targeted control in which SIRPα-inhibited macrophages were incubated with 2.1 μm lacking anti-streptavidin. These were not engulfed. After pre-incubation of the mixtures for up to 150 min, mixtures were plated for 24 hr on top of 5-μm pore transwells. Cells collected from transwell tops and bottoms were stained for CD11b+,F4/80+ and analyzed by flow cytometry for engulfment (STAR Methods).

Journal: Current biology : CB

Article Title: SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors

doi: 10.1016/j.cub.2017.06.005

Figure Lengend Snippet: (A) Marrow macrophages were engineered and mixed with streptavidin beads of 900 nm to 6.7 μm diameter or else with disaggregated tdTom A549 tumors. Beads are opsonized with anti-streptavidin except for a non-targeted control in which SIRPα-inhibited macrophages were incubated with 2.1 μm lacking anti-streptavidin. These were not engulfed. After pre-incubation of the mixtures for up to 150 min, mixtures were plated for 24 hr on top of 5-μm pore transwells. Cells collected from transwell tops and bottoms were stained for CD11b+,F4/80+ and analyzed by flow cytometry for engulfment (STAR Methods).

Article Snippet: REAGENT OR RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti-human SIRPα (clone SE7C2) Santa Cruz sc-23863 Rat anti-mouse SIRPα (clone P84) BD Biosciences 552371 Rabbit anti-human RBCs (polyclonal) Rockland 109-4139 Anti-human CD41-FITC (HIP8) Biolegend 303703 Anti-human CD47-FITC (Clone CC2C6) Biolegend 323106 Rat Anti-human CD47 (Clone B6H12) BD Biosciences 556044 Anti-mouse CD11b-PE/Cy7 (Clone M1/70) Biolegend 101215 Anti-mouse F4/80-APC/Cy7 (clone BM8) Biolegend 123113 Donkey Anti-rabbit AF488 ThermoFisher A-21206 Donkey Anti-rabbit AF647 ThermoFisher A-31573 IgG from rabbit serum Sigma I5006-10MG Mouse anti-human Mucin (Clone S.854.6) ThermoFisher MA5-15131 Cetuximab InVivogen hegfr-mab1 Goat anti-rabbit AF700 ThermoFisher A-21038 Goat anti-rat AF647 ThermoFisher A-21247 Anti-mouse Ly-6G (Gr-1) APC (Clone RB6-8C5) Biolegend 108411 Anti-mouse CD135-BV421 (Clone A2F10.1) Biosciences 562898 Anti-mouse SIRPα-FITC (Clone P84) Biosciences 144005 Anti-human CD14-BV421 (Clone HCD14) Biolegend 325627 Anti-human CD33-APC (Clone WM53) Biolegend 303407 Anti-human CD66-PerCP/Cy5.5 (Clone G10F5) Biolegend 305107 Biological Samples Human Bone Marrow AllCells ABM001-1 NSG Mice The Jackson Laboratory 5557 Chemicals, Peptides, and Recombinant Proteins 7-Amino-actinomycin D Sigma A9400-1MG Hoechst 33342 ThermoFisher H3570 Phorbol myristate acetate Sigma P8139-1MG CFDA-SE ThermoFisher V12883 RBC Lysis Buffer Sigma R7757 Dispase StemCell Technologies 7913 Collagenase Sigma C0130-100MG DNase I Sigma 11284932001 Anti-streptavidin (polyclonal) Sigma S6390 Critical Commercial Assays F(Ab′)2 Preparation Kit ThermoFisher 44988 SIRPα ShRNA Lentiviral Plasmid Santa Cruz sc-44106-SH Streptavidin Beads ThermoFisher 11205D RNeasy plus Mini Kit QIAGEN 74134 TruSeq Stranded mRNA Library Prep kit Illumina RS-122-2101 Cell Lines Human adenocarcinoma (A549) ATCC CCL-185 Human Monocyte (THP-1) ATCC TIB-202 Primary liver carcinoma (EC4) Chi Van Dang’s Lab N/A Mesenchymal Stem Cells Progeria Research Foundation N/A Human hepatocellular carcinoma (HepG2) ATCC HB-8065 Mouse myoblast (C2C12) ATCC CRL-1772 Software MaxQuant Version 1.5.3.8 Max Planck Institute of Biochemistry http://www.biochem.mpg.de/5111795/maxquant Living Image Perkin Elmer http://www.perkinelmer.com/product/spectrum-200-living-image-v4series-1-128113 ImageJ NIH https://imagej.nih.gov/ij/ Open in a separate window KEY RESOURCES TABLE

Techniques: Incubation, Staining, Flow Cytometry

(A) Sirpa:Cd47 ratios increase in macrophages from microenvironments of increasing stiffness.

Journal: Current biology : CB

Article Title: SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors

doi: 10.1016/j.cub.2017.06.005

Figure Lengend Snippet: (A) Sirpa:Cd47 ratios increase in macrophages from microenvironments of increasing stiffness.

Article Snippet: REAGENT OR RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti-human SIRPα (clone SE7C2) Santa Cruz sc-23863 Rat anti-mouse SIRPα (clone P84) BD Biosciences 552371 Rabbit anti-human RBCs (polyclonal) Rockland 109-4139 Anti-human CD41-FITC (HIP8) Biolegend 303703 Anti-human CD47-FITC (Clone CC2C6) Biolegend 323106 Rat Anti-human CD47 (Clone B6H12) BD Biosciences 556044 Anti-mouse CD11b-PE/Cy7 (Clone M1/70) Biolegend 101215 Anti-mouse F4/80-APC/Cy7 (clone BM8) Biolegend 123113 Donkey Anti-rabbit AF488 ThermoFisher A-21206 Donkey Anti-rabbit AF647 ThermoFisher A-31573 IgG from rabbit serum Sigma I5006-10MG Mouse anti-human Mucin (Clone S.854.6) ThermoFisher MA5-15131 Cetuximab InVivogen hegfr-mab1 Goat anti-rabbit AF700 ThermoFisher A-21038 Goat anti-rat AF647 ThermoFisher A-21247 Anti-mouse Ly-6G (Gr-1) APC (Clone RB6-8C5) Biolegend 108411 Anti-mouse CD135-BV421 (Clone A2F10.1) Biosciences 562898 Anti-mouse SIRPα-FITC (Clone P84) Biosciences 144005 Anti-human CD14-BV421 (Clone HCD14) Biolegend 325627 Anti-human CD33-APC (Clone WM53) Biolegend 303407 Anti-human CD66-PerCP/Cy5.5 (Clone G10F5) Biolegend 305107 Biological Samples Human Bone Marrow AllCells ABM001-1 NSG Mice The Jackson Laboratory 5557 Chemicals, Peptides, and Recombinant Proteins 7-Amino-actinomycin D Sigma A9400-1MG Hoechst 33342 ThermoFisher H3570 Phorbol myristate acetate Sigma P8139-1MG CFDA-SE ThermoFisher V12883 RBC Lysis Buffer Sigma R7757 Dispase StemCell Technologies 7913 Collagenase Sigma C0130-100MG DNase I Sigma 11284932001 Anti-streptavidin (polyclonal) Sigma S6390 Critical Commercial Assays F(Ab′)2 Preparation Kit ThermoFisher 44988 SIRPα ShRNA Lentiviral Plasmid Santa Cruz sc-44106-SH Streptavidin Beads ThermoFisher 11205D RNeasy plus Mini Kit QIAGEN 74134 TruSeq Stranded mRNA Library Prep kit Illumina RS-122-2101 Cell Lines Human adenocarcinoma (A549) ATCC CCL-185 Human Monocyte (THP-1) ATCC TIB-202 Primary liver carcinoma (EC4) Chi Van Dang’s Lab N/A Mesenchymal Stem Cells Progeria Research Foundation N/A Human hepatocellular carcinoma (HepG2) ATCC HB-8065 Mouse myoblast (C2C12) ATCC CRL-1772 Software MaxQuant Version 1.5.3.8 Max Planck Institute of Biochemistry http://www.biochem.mpg.de/5111795/maxquant Living Image Perkin Elmer http://www.perkinelmer.com/product/spectrum-200-living-image-v4series-1-128113 ImageJ NIH https://imagej.nih.gov/ij/ Open in a separate window KEY RESOURCES TABLE

Techniques:

KEY RESOURCES TABLE

Journal: Current biology : CB

Article Title: SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors

doi: 10.1016/j.cub.2017.06.005

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: REAGENT OR RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti-human SIRPα (clone SE7C2) Santa Cruz sc-23863 Rat anti-mouse SIRPα (clone P84) BD Biosciences 552371 Rabbit anti-human RBCs (polyclonal) Rockland 109-4139 Anti-human CD41-FITC (HIP8) Biolegend 303703 Anti-human CD47-FITC (Clone CC2C6) Biolegend 323106 Rat Anti-human CD47 (Clone B6H12) BD Biosciences 556044 Anti-mouse CD11b-PE/Cy7 (Clone M1/70) Biolegend 101215 Anti-mouse F4/80-APC/Cy7 (clone BM8) Biolegend 123113 Donkey Anti-rabbit AF488 ThermoFisher A-21206 Donkey Anti-rabbit AF647 ThermoFisher A-31573 IgG from rabbit serum Sigma I5006-10MG Mouse anti-human Mucin (Clone S.854.6) ThermoFisher MA5-15131 Cetuximab InVivogen hegfr-mab1 Goat anti-rabbit AF700 ThermoFisher A-21038 Goat anti-rat AF647 ThermoFisher A-21247 Anti-mouse Ly-6G (Gr-1) APC (Clone RB6-8C5) Biolegend 108411 Anti-mouse CD135-BV421 (Clone A2F10.1) Biosciences 562898 Anti-mouse SIRPα-FITC (Clone P84) Biosciences 144005 Anti-human CD14-BV421 (Clone HCD14) Biolegend 325627 Anti-human CD33-APC (Clone WM53) Biolegend 303407 Anti-human CD66-PerCP/Cy5.5 (Clone G10F5) Biolegend 305107 Biological Samples Human Bone Marrow AllCells ABM001-1 NSG Mice The Jackson Laboratory 5557 Chemicals, Peptides, and Recombinant Proteins 7-Amino-actinomycin D Sigma A9400-1MG Hoechst 33342 ThermoFisher H3570 Phorbol myristate acetate Sigma P8139-1MG CFDA-SE ThermoFisher V12883 RBC Lysis Buffer Sigma R7757 Dispase StemCell Technologies 7913 Collagenase Sigma C0130-100MG DNase I Sigma 11284932001 Anti-streptavidin (polyclonal) Sigma S6390 Critical Commercial Assays F(Ab′)2 Preparation Kit ThermoFisher 44988 SIRPα ShRNA Lentiviral Plasmid Santa Cruz sc-44106-SH Streptavidin Beads ThermoFisher 11205D RNeasy plus Mini Kit QIAGEN 74134 TruSeq Stranded mRNA Library Prep kit Illumina RS-122-2101 Cell Lines Human adenocarcinoma (A549) ATCC CCL-185 Human Monocyte (THP-1) ATCC TIB-202 Primary liver carcinoma (EC4) Chi Van Dang’s Lab N/A Mesenchymal Stem Cells Progeria Research Foundation N/A Human hepatocellular carcinoma (HepG2) ATCC HB-8065 Mouse myoblast (C2C12) ATCC CRL-1772 Software MaxQuant Version 1.5.3.8 Max Planck Institute of Biochemistry http://www.biochem.mpg.de/5111795/maxquant Living Image Perkin Elmer http://www.perkinelmer.com/product/spectrum-200-living-image-v4series-1-128113 ImageJ NIH https://imagej.nih.gov/ij/ Open in a separate window KEY RESOURCES TABLE

Techniques: Recombinant, Lysis, shRNA, Plasmid Preparation, Software

Fig. 1. TREM-1 expression was up-regulated in mice infected with Schistosoma japonicum at 6 weeks after infection and then decreased. The number of TREM- 1 + cells in total F4/80 +CD11b+ peritoneal macrophages was increased in mice infected with Schistosoma japonicum at 6 weeks, compared to that from uninfected mice (*P < 0.05). Then the number of TREM-1 + cells in total F4/80 +CD11b+ peritoneal macrophages was decreased after 6 weeks after infection.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Recombinant P40 protein of Schistosoma japonicum inhibits TREM-1 expression in RAW264.7 cells via FOXO3a.

doi: 10.1016/j.biopha.2022.112826

Figure Lengend Snippet: Fig. 1. TREM-1 expression was up-regulated in mice infected with Schistosoma japonicum at 6 weeks after infection and then decreased. The number of TREM- 1 + cells in total F4/80 +CD11b+ peritoneal macrophages was increased in mice infected with Schistosoma japonicum at 6 weeks, compared to that from uninfected mice (*P < 0.05). Then the number of TREM-1 + cells in total F4/80 +CD11b+ peritoneal macrophages was decreased after 6 weeks after infection.

Article Snippet: The associated antibodies included PE conjugated antibody against mouse F4/80 (02922–60–100, 0.2 μg, Biogems, USA), PE-Cy7 conjugated antibody against mouse CD11b (03221–77–25, 0.1 μg, Biogems, USA), eFluor 660 conjugated antibody against mouse TREM-1 (50–3541–80, 0.1 μg, eBioscience, USA).

Techniques: Expressing, Infection